Advanced Biomed Inc. (ADVB): Nasdaq/NYSE listing notice — Advanced Biomed faces Nasdaq delisting after failing minimum bid price; appeals with reverse split plan

Advanced Biomed Inc.

Failed to regain minimum $1.00 bid price by Jan 14, 2026; Nasdaq notified delisting effective Jan 27, 2026.
Company appealed on Jan 21, 2026, staying suspension pending Nasdaq hearings panel decision.
Regain compliance plan includes reverse stock split approved Jan 12, 2026, effective on/after Feb 13, 2026.
No assurance that panel will grant continued listing or that compliance will be achieved.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.97

Advanced Biomed Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

January 16, 2026, the Staff notified the Company that its securities would be scheduled for delisting from The Nasdaq Capital Market and suspended at the opening of business on January 27, 2026, unless the Company requested an appeal of this determination by January 23, 2026 before a Hearings Panel (the “Panel”). On January 21, 2026, the Company appealed the Staff’s delisting determination by submitting a hearing request to the Panel, which stayed the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision. The Company expects to present to the Pan

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Advanced Biomed Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-006281

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.